Therefore, SMTNL1 may be a feasible therapeutic target for progesterone-dependent inhibition of endometrial epithelial cells during hyperglycemia and insulin-sensitizing endometrium in gestational diabetes or other metabolic disorders. This evidence concerns the gene INS and Other metabolic disease.